Invests in
Sectors:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- TW
- CE
Lists including Wei
Investments
Work Experience
2021
Senior Director, Venture Investments, JJDC
2021
JJDC is the strategic corporate venture capital group for Johnson & Johnson; launched in 1973, it is one of the longest-running and most reputable CVC in health care. I cover investments in areas of strategic interest to Johnson & Johnson. In support of J&J strategic objectives, I work closely with R&D Therapeutic Areas, Innovation Centers, JLabs, Business Development, Commercial, and other functions. 2022-2023, Global assignment in Shanghai China
2025
Board Member
2025
Prazer Therapeutics is a biotech company focusing on developing new drugs based on Targeted Protein Degradation (TPD) technology with unique design and characteristics.
Investor
2024
Kaken (TSE: 4521) is a pharmaceutical conglomerate headquartered in Japan with a diverse drug pipeline for various disease areas
2023
Board Member
2023
Circode develops novel RNA therapeutics for multiple disease areas
2022
Board Observer
2022
DAC Biotechnology is an antibody-drug-conjugate (ADC) company that has established an end-to-end capability for ADC generation and an innovative pipeline in pre-clinical and clinical stages.
2021 - 2021
Board Member
2021 - 2021
ImmPact Bio is pioneering a novel strategy to surmount a major challenge compromising current T-cell (CAR-T) therapy. Acquired by Lyell Immunopharma (LYEL) in 2024.
2020 - 2021
Board Observer
2020 - 2021
Actym Therapeutics is developing a microbial-based immunotherapy platform for various challenging cancer types.
2019 - 2021
Senior Associate
2019 - 2021
Illumina Ventures is an independently managed fund focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. We invest in life science tools, therapeutics, clinical diagnostics, and other opportunities to improve human health. Covered investments: Actym Therapeutics, Kallyope, Encoded Therapeutics.
2019 - 2020
Advisory Board Member
2019 - 2020
Immunotherapies for cancer
2017 - 2019
Director, Healthcare Investment and Business Development
2017 - 2019
BOE Technology Group is a FORBES global2000 company headquartered in Beijing, China. -Lead all aspects of sourcing and deal execution in healthcare business -Manage collaboration projects, investment portfolio, and LP-GP relationship -Recruitment, training, and team building -Corporate strategy and business development -PR/marketing/ecosystem expansion